Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVAX | US
-0.14
-4.35%
Healthcare
Biotechnology
30/06/2024
09/03/2026
3.08
3.12
3.28
3.03
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
73.6%1 month
71.0%3 months
96.5%6 months
143.8%-
3.57
12.06
8.37
0.69
-0.59
63.35
-
-18.80M
17.18M
17.18M
-
-2.97K
-
-
-802.80
0.90
2.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.58
Range1M
0.69
Range3M
4.05
Rel. volume
1.30
Price X volume
102.88K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.89 | 18.85M | 0.53% | n/a | 3.49% |
| NRXP | NRXP | Biotechnology | 1.73 | 18.60M | 1.76% | n/a | -46.73% |
| IO Biotech Inc. Common Stock | IOBT | Biotechnology | 0.28 | 18.45M | -6.82% | n/a | 2.23% |
| PLUR | PLUR | Biotechnology | 3.37 | 18.43M | 2.74% | n/a | 30845.83% |
| Cue Biopharma Inc | CUE | Biotechnology | 0.301 | 18.12M | 0.40% | n/a | 52.09% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 1.99 | 17.75M | 2.31% | n/a | 0.00% |
| NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 0.8404 | 16.65M | -2.96% | n/a | -2.11% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.615 | 16.64M | 1.20% | n/a | 1.90% |
| GeoVax Labs Inc | GOVX | Biotechnology | 1.92 | 16.37M | 7.26% | n/a | -6.03% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.61 | 16.05M | 3.57% | n/a | 54.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | 0.53 | Cheaper |
| Ent. to Revenue | 63.35 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 96.46 | 72.80 | Riskier |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 17.18M | 3.66B | Emerging |